drugset

drugset / Trial / NCT00871559

A Multiple-Ascending-Dose Study of the Safety and Tolerability of REGN421(SAR153192) in Patients With Advanced Solid Malignancies

NCT00871559 ↗

Phase 1 Completed 83 enrolled Regeneron Pharmaceuticals Sanofi · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the safety and tolerability of REGN421 (SAR153192) in patients with advanced solid malignancies.

Timeline

Start: 2009-06
Primary completion: 2014-02
Completion: 2014-02

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ENOTICUMAB	Monoclonal antibody	—	—

Indications